The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Status and phase: Unknown; Phase 2

Conditions: Unstable Angina; Coronary Heart Disease; Blood Stasis Syndrome

Treatments: Drug: Xuesaitong soft capsule; Drug: Xuesaitong soft capsule Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01615003

NNSF81173116

Details and patient eligibility

About

In this study, typical cases of blood stasis syndrome of coronary heart disease are selected, by using microRNA chip, cDNA microarray and other bioinformatics technologies to filter and verify related miRNA and its target gene of Coronary Heart disease. Meanwhile, intervene by Xuesaitong soft capsules to investigate related miRNA and its target gene of Coronary Heart disease.

Enrollment: 70 estimated patients

Sex: All

Ages: 30 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of coronary angiography unstable angina
• Clinical diagnosis of unstable angina
• Age of 30 to 75 years old
• Not use thrombolysis, dilate coronary drugs within two weeks
• Tongue dark
• Sign the consent

Exclusion criteria

• Severe valvular heart disease
• Insulin-dependent diabetes
• mental disease
• Combined with severe liver, kidney, hematopoietic system disorder
• Patients with malignant tumors
• Pregnancy or breast-feeding women
• Recent history of trauma
• Drug allergy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

70 participants in 2 patient groups, including a placebo group

Xuesaitong soft capsule group

Experimental group

Description:

Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.

Treatment:

Drug: Xuesaitong soft capsule

control group

Placebo Comparator group

Description:

Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.

Treatment:

Drug: Xuesaitong soft capsule Placebo